|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations</b>: CGGA: Chinese Glioma Genome Atlas; TCGA: The Cancer Genome Atlas; TAMs: Tumor associated macrophages; IDH: isocitrate dehydrogenase; GBM: glioblastoma.
|
31143523 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified a subset of tumors (n = 18, 8.8% of high-grade gliomas) exhibiting moderate-to-strong immunoreactivity that enriched for the IDH-wild-type glioblastoma variants gliosarcoma (n = 10) and the newly described epithelioid glioblastoma (n = 4).
|
28789475 |
2017 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Some findings, such as that of IDH mutation in low-grade gliomas and secondary glioblastoma (GBM), fit well into established notions of different routes of gliomagenesis.
|
21465149 |
2011 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1<sup>R132H</sup>-negative GBM showed higher ALK expression compared with IDH-mutant GBM (65.2% vs 20%).
|
27993946 |
2017 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The presented approach is applicable for prospective validation and appears promising towards an effective glioblastoma patient stratification in addition to IDH mutations.
|
23250732 |
2013 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Differential expression of circRNAs may be associated with IDH-wt glioblastoma development and progression, and these circRNAs can be identified as biomarkers for prognosis prediction and targets for treatment.
|
29920451 |
2018 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
|
28421459 |
2017 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on the new histomolecular classification, diagnoses included anaplastic oligodendroglioma IDH mutant and 1p/19q-codeleted (32.5 %), anaplastic astrocytoma IDH mutant (IDH (mut)) (11.0 %), anaplastic astrocytoma IDH wild type (IDH (wt)) (5.3 %), glioblastoma IDH (mut) (17.1 %), and glioblastoma IDH (wt) (33.2 %).
|
27573687 |
2016 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In spite of a recent surge in elucidating the tumorigenic activity of IDH mutations in glioblastoma, the underlying biological mechanisms remain poorly understood.
|
22309944 |
2012 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Subsequent studies have confirmed recurrent IDH1 and IDH2 mutations in up to 70% of low-grade glioma and secondary GBM, as well as in 10% of acute myeloid leukemia (AML) cases.
|
20692206 |
2010 |
|
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Addition of 2-HG to glioblastoma cultures recapitulates the effects of the IDH mutation on intrinsic apoptosis, shuts down oxidative phosphorylation and reduces ATP levels in glioblastoma cells.
|
29057925 |
2017 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
MGMT promoter methylation status is currently the only established molecular prognosticator in IDH wild-type glioblastoma multiforme (GBM).
|
26934681 |
2016 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
From Jan 2009 to Dec 2016, 161 patients with newly diagnosed IDH-wild type GB were treated with surgery and adjuvant concurrent chemoradiotherapy with the Stupp's regimen, and then genomic research proceeded with their surgical specimens.
|
30773189 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the absence of IDH mutation, several genes associated with metabolism are differentially expressed in these subtypes of primary GBM, implicating metabolic reprogramming occurs in tumor microenvironment.
|
28278055 |
2017 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overexpression of IDH1(R132H) and IDH2(R172K) mutant protein in glioblastoma cells resulted in increased radiation sensitivity and altered ROS metabolism and suppression of growth and migration in vitro.
|
23115158 |
2013 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The total NADPH production capacity in glioblastoma was provided for 65% by IDH activity and the occurrence of IDH1 (R132 ) mutation reduced this capacity by 38%.
|
20127344 |
2010 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
|
25150284 |
2014 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Consequently, we present a curated panel of 12 readily-usable, genetically-diverse, tumourigenic, patient-derived, low-passage, serum-free cell lines representing the spectrum of molecular subtypes of IDH-wildtype GBM along with their detailed phenotypic characterisation plus a bespoke set of lentiviral plasmids for bioluminescent/fluorescent labelling, gene expression and CRISPR/Cas9-mediated gene inactivation.
|
30894629 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Doomed from the TERT? A Two-Stage Model of Tumorigenesis in IDH-Wild-Type Glioblastoma.
|
30991024 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
|
26503470 |
2015 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutations of isocitrate dehydrogenase isoform 1 and 2 (IDH1 and IDH2) genes have been identified in glioblastoma and acute myeloid leukemia (AML).
|
25486927 |
2015 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
T1+Gad performed best for IDH typing of glioblastoma (sensitivity 91.9%, specificity 100%, AUC 0.945) and ADC for non-Gadolinium-enhancing gliomas (sensitivity 85.7%, specificity 78.4%, AUC 0.877).
|
30927935 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Within the molecularly-defined IDH wild-type GBM cohort, younger patients had significantly more mutations in PDGFRA, PTPN11, SMARCA4, BRAF and TP53.
|
27579614 |
2016 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
IDH-wild-type glioblastoma (GBM) is a disease with devastating prognosis.
|
31736002 |
2020 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Oncogenic mutations in two isocitrate dehydrogenase (IDH)-encoding genes (IDH1 and IDH2) have been identified in acute myelogenous leukemia, low-grade glioma, and secondary glioblastoma (GBM).
|
28564604 |
2017 |